Acebrophylline (100mg) + Acetylcysteine (600mg) is a fixed-dose combination (FDC) medication used primarily as a mucolytic and bronchodilator for the management of obstructive airway diseases. Acebrophylline is a xanthine derivative with bronchodilatory and anti-inflammatory properties, while Acetylcysteine is a mucolytic agent that breaks down disulfide bonds in mucus proteins, reducing viscosity. This combination is widely used in the Indian market for conditions like Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis with excessive, tenacious mucus.
Adult: One capsule/tablet (Acebrophylline 100mg + Acetylcysteine 600mg) twice daily, preferably after meals.
Note: Administer orally after food to minimize gastric irritation. Swallow the capsule/tablet whole with a full glass of water. Do not crush or chew. Maintain adequate hydration to aid mucolytic action.
The combination works synergistically. Acebrophylline acts as a bronchodilator and anti-inflammatory agent by inhibiting phosphodiesterase (PDE) enzymes (particularly PDE IV), leading to increased intracellular cAMP. It also antagonizes adenosine receptors. Acetylcysteine acts as a mucolytic by breaking disulfide bonds (-S-S-) in mucoproteins, reducing mucus viscosity and elasticity. It also has antioxidant properties by serving as a precursor to glutathione, scavenging free radicals in the respiratory tract.
Pregnancy: Category C (US FDA). Animal studies show risk; human data insufficient. Use only if potential benefit justifies potential fetal risk. Avoid in first trimester unless absolutely necessary.
Driving: May cause dizziness, nervousness, or blurred vision. Patients should be cautioned about operating machinery or driving until they know how the medication affects them.
| Ciprofloxacin/Enoxacin | Markedly increases Acebrophylline (Theophylline) levels, risk of toxicity | Major |
| Phenobarbital, Carbamazepine, Rifampicin | Decreases Acebrophylline levels, reducing efficacy | Major |
| Warfarin | Acebrophylline may potentiate anticoagulant effect; increased INR risk | Major |
| Beta-blockers (e.g., Propranolol) | Antagonistic effect on bronchodilation | Moderate |
| Digoxin | Acebrophylline may slightly decrease Digoxin levels | Moderate |
| Nitroglycerin | Synergistic vasodilation may cause headache, hypotension | Moderate |
| Activated Charcoal | Reduces absorption of Acebrophylline | Moderate |
| Antitussives (e.g., Codeine) | Counteracts mucolytic effect of Acetylcysteine; avoid combination | Moderate |
Same composition (Acebrophylline (100mg) + Acetylcysteine (600mg)), different brands: